Pyxis Oncology PYXS
NASDAQ PYXS
$1.64 +0.01 (+0.61%)
At close: Nov 11, 2026 · 4:00 PM EST

Pyxis Oncology (PYXS) Receivables (2024 - 2025)

Updated

Pyxis Oncology's Receivables was $3 million in Q2 2025.

Analysis

Pyxis Oncology (PYXS) Receivables (2024 - 2025) Analysis & Trends

  • The Q2 2025 figure marks the highest quarterly Receivables since Q1 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 25.23 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 18.99 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 13.51 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 12.74 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 16.16 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 10.35 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 5.01 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 14.19 Bn
10 Pyxis Oncology 136.12 Mn -60.32 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 3.00 Mn
Mar 31, 2024 8.00 Mn
API Access

Pyxis Oncology Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables&ticker=PYXS&period=max&api_key=YOUR_API_KEY